News and Announcements
BioProspect Cuts New Deal with WA Biotech
- Published January 21, 2012 1:59PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
BIOPROSPECT has rejigged its licensing arrangement with unlisted Western Australian biotech company Bio-Gene for the Qcide natural insecticide, announcing it has agreed to assign the intellectual property to Bio-Gene for cash and an increased royalty share.
Under the original deal between the two companies, announced in mid-2008, Bio-Gene paid BioProspect $100,000 up-front for the rights to commercialise the product, which is derived from the oil of the Gympie Messmate (Eucalyptus cloeziana), and would also pay a flat 2% royalty on sales of any products that made it to market.
——-
To view the full article, please click the link below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
